UBE2M

Across TCGA pan-cancer cohorts, UBE2M RNA is linked to patient survival in 29 of 34 cancer types, making it the most broadly survival-associated UBE2M data layer compared with 5 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher UBE2M RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE2M expression acts as an unfavorable survival marker, although some lineages such as SCLC and GBM show a favorable association.

ACC, LUAD, and MESO are the cancer types where UBE2M RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.255	0.671	<.001	89	view →
LUAD	OS	Median	All	0.755	0.864	<.001	84	view →
MESO	OS	Median	All	0.414	0.660	<.001	66	view →
LIHC	OS	Tertile	All	0.574	0.769	<.001	64	view →
UVM	DFS	Tertile	II,III,IV	0.424	0.844	<.001	52	view →
KIRP	DFS	Quartile	All	0.814	0.962	.001	40	view →
LGG	DFS	Median	All	0.654	0.822	<.001	37	view →
SCLC	OS	Tertile	All	0.621	0.379	.015	22	view →
KIRC	DFS	Median	IV	0.269	0.618	.011	17	view →
TGCT	DFS	Tertile	All	0.729	0.943	.002	16	view →
PRAD	DFS	Tertile	All	0.895	0.966	.006	16	view →
KICH	DFS	Tertile	III,IV	0.056	0.849	.005	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 29 lineages.

UBE2M–ACC (DFS)

Open the ACC breakdown →